Point72 Asset Management L.P. lessened its stake in Crispr Therapeutics AG (NASDAQ:CRSP) by 8.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,456 shares of the company’s stock after selling 600 shares during the quarter. Point72 Asset Management L.P.’s holdings in Crispr Therapeutics were worth $265,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of CRSP. NEXT Financial Group Inc lifted its holdings in Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the period. Benjamin Edwards Inc. raised its stake in shares of Crispr Therapeutics by 96.4% in the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares during the period. Coastal Investment Advisors Inc. bought a new stake in shares of Crispr Therapeutics in the third quarter valued at $26,000. US Bancorp DE raised its stake in shares of Crispr Therapeutics by 553.7% in the second quarter. US Bancorp DE now owns 621 shares of the company’s stock valued at $29,000 after buying an additional 526 shares during the period. Finally, BSW Wealth Partners bought a new stake in shares of Crispr Therapeutics in the second quarter valued at $39,000. Institutional investors own 49.82% of the company’s stock.
Several analysts have issued reports on the company. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, November 1st. William Blair upgraded Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Goldman Sachs Group boosted their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, November 19th. Roth Capital boosted their target price on Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $71.38.
Shares of CRSP traded down $4.17 during midday trading on Monday, reaching $61.84. The stock had a trading volume of 1,473,420 shares, compared to its average volume of 720,811. The company’s 50-day moving average is $65.47 and its 200 day moving average is $50.80. Crispr Therapeutics AG has a 12-month low of $27.11 and a 12-month high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $3.41 billion, a price-to-earnings ratio of -17.98 and a beta of 3.30.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. Research analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current fiscal year.
In other Crispr Therapeutics news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares of the company’s stock, valued at approximately $2,353,260. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $62.00, for a total value of $465,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is currently owned by corporate insiders.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
See Also: Accumulation/Distribution
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.